Business Context and Reporting Period
Cognition Therapeutics, Inc. (CGTX), a Delaware corporation and emerging growth company, filed this Form 8-K to report the results of its Annual Meeting of Stockholders held on June 18, 2025. The meeting was conducted virtually.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the final voting outcomes for two proposals submitted to stockholders:
- Proposal 1: Election of Class I Directors
- Peggy Wallace: Elected with 8,566,458 votes "For" and 2,590,981 votes "Withheld". There were 22,760,336 Broker Non-Votes.
- Ellen B. Richstone: Elected with 8,686,877 votes "For" and 2,470,562 votes "Withheld". There were 22,760,336 Broker Non-Votes.
- Both directors will serve until the 2028 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accountants
- Ernst & Young LLP was ratified as the independent auditor for the 2025 fiscal year.
- Votes: 33,457,921 "For", 327,242 "Against", and 132,612 "Abstentions". There were no Broker Non-Votes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the administrative results of the stockholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 28, 2025, for detailed biographies of the elected directors and the full context of the proposals.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast versus total voting power, noting the significant number of Broker Non-Votes on the director election.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K does not include financial metrics.